Reuters logo
BRIEF-Oramed announces end-of-phase 2 meeting with FDA to initiate phase 3 program
July 11, 2017 / 12:59 PM / 2 months ago

BRIEF-Oramed announces end-of-phase 2 meeting with FDA to initiate phase 3 program

July 11 (Reuters) - Oramed Pharmaceuticals Inc:

* Oramed announces end-of-phase 2 meeting with FDA to initiate phase 3 program

* Oramed Pharmaceuticals-‍phase IIB trial met primary & secondary endpoints by indicating a statistically significant lowering of glucose relative to placebo​

* Oramed - ‍FDA agreed to schedule an end-of-phase II meeting with co for phase IIB trial of oral insulin capsule ORMD-0801 in treatment of type 2 diabetes​

* Oramed Pharmaceuticals Inc says end-of-phase II meeting is expected to take place on August 31, 2017

* Oramed Pharmaceuticals-FDA agreed to schedule end-of-phase II meeting with co for completed phase IIB trial of ORMD-0801 in treatment of type 2 diabetes​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below